Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LSTA Stock Forecast 2026-2027
$3.70
Current Price
$33.69M
Market Cap
Buy 0
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to LSTA Price Targets
+8.1%
To High Target of $4.00
+8.1%
To Median Target of $4.00
+8.1%
To Low Target of $4.00
LSTA Price Momentum
+13.1%
1 Week Change
+3.9%
1 Month Change
+40.7%
1 Year Change
+98.9%
Year-to-Date Change
-27.0%
From 52W High of $5.07
+104.4%
From 52W Low of $1.81
📊 TOP ANALYST CALLS
Did LSTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lisata Therapeutics is one of their latest high-conviction picks.
Latest LSTA Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, LSTA has a neutral consensus with a median price target of $4.00 (ranging from $4.00 to $4.00). The overall analyst rating is Buy (6.0/10). Currently trading at $3.70, the median forecast implies a 8.1% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LSTA Analyst Ratings
0
Buy
2
Hold
0
Sell
LSTA Price Target Range
Low
$4.00
Average
$4.00
High
$4.00
Current: $3.70
Latest LSTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LSTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | Joseph Pantginis | Neutral | Downgrade | $N/A |
| Jan 21, 2026 | Brookline Capital | Hold | Downgrade | $N/A | |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 15, 2025 | Brookline Capital | Buy | Maintains | $N/A | |
| Dec 11, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 21, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 18, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 19, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 21, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 26, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 25, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 1, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 15, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 25, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 31, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 19, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Lisata Therapeutics Inc. (LSTA) Competitors
The following stocks are similar to Lisata Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lisata Therapeutics Inc. (LSTA) Financial Data
Lisata Therapeutics Inc. has a market capitalization of $33.69M with a P/E ratio of -2.0x. The company generates $170,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -10,178.8% and return on equity of -91.4%.
Valuation Metrics
Market Cap
$33.69M
Enterprise Value
$16.46M
P/E Ratio
-2.0x
PEG Ratio
0.2x
Price/Sales
175.2x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-10,178.8%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+38.8%
Current Ratio
4.2x
Debt/Equity
0.0x
ROE
-91.4%
ROA
-50.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lisata Therapeutics Inc. (LSTA) Business Model
About Lisata Therapeutics Inc.
What They Do
Develops innovative therapies for advanced solid tumors.
Business Model
Lisata Therapeutics Inc. operates in the oncology sector, focusing on the discovery and commercialization of therapies for serious diseases. The company generates revenue through its clinical-stage products, particularly its lead investigational product, certepetide, which utilizes a unique technology to enhance the effectiveness of anti-cancer drugs. Strategic partnerships and licensing agreements further support its business model.
Additional Information
Founded in 1980 and based in Basking Ridge, New Jersey, Lisata has a diverse clinical pipeline targeting various cancers and is actively engaged in trials for conditions with significant unmet medical needs. The company collaborates with organizations like Catalent and GATC Health to bolster its research and development capabilities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
26
CEO
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
Country
United States
IPO Year
N/A
Website
www.lisata.comLisata Therapeutics Inc. (LSTA) Latest News & Analysis
Latest News
Quick Summary
Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (NASDAQ: LSTA) for potential recoverable losses under federal securities laws for affected investors.
Why It Matters
The investigation into Lisata Therapeutics may indicate potential legal issues or financial mismanagement, impacting stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)
28 days ago
Quick Summary
Brodsky & Smith is investigating potential claims against Lisata Therapeutics' Board for breaches of fiduciary duty related to its sale to Kuva Labs for $4.00 per share plus contingent payments.
Why It Matters
The investigation into Lisata Therapeutics' board may signal potential legal issues and affect shareholder value, raising concerns about the fairness of the acquisition deal.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Lisata Therapeutics Inc (LSTA) will be acquired by Kuva Labs Inc for $4 per share in cash, with an additional contingent value right of up to $3 per share based on drug development milestones.
Why It Matters
Lisata Therapeutics' acquisition at $4 per share, plus potential extra value, signals a positive outlook on its drug pipeline, influencing investor sentiment and valuation.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Lisata stockholders will receive $4.00 per share in cash at closing, plus a non-tradeable contingent value right for potential additional payments of up to $3.00 per share based on milestones.
Why It Matters
Lisata stockholders gain immediate cash and potential future payouts, indicating a structured exit strategy that could enhance shareholder value depending on milestone achievements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
2 months ago
Quick Summary
Insiders could gain significant financial advantages not accessible to regular shareholders.
Why It Matters
Insider benefits can indicate potential misalignment of interests, affecting stock performance and shareholder value, which may lead to investor caution or action.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lisata Therapeutics to be acquired by Kuva Labs
4 months ago
Quick Summary
Lisata Therapeutics (NASDAQ:LSTA) will be acquired by Kuva Labs for $5 per share in cash, plus one contingent value right per share, as per a definitive agreement.
Why It Matters
Lisata's acquisition by Kuva Labs at $5 per share signals a premium valuation, impacting shareholder returns and market perception of both companies' growth potential.
Source: Proactive Investors
Market Sentiment:
Positive
Frequently Asked Questions About LSTA Stock
What is Lisata Therapeutics Inc.'s (LSTA) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Lisata Therapeutics Inc. (LSTA) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $4.00.
Is LSTA stock a good investment in 2027?
According to current analyst ratings, LSTA has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LSTA stock?
Wall Street analysts predict LSTA stock could reach $4.00 in the next 12 months. This represents a 8.1% increase from the current price of $3.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lisata Therapeutics Inc.'s business model?
Lisata Therapeutics Inc. operates in the oncology sector, focusing on the discovery and commercialization of therapies for serious diseases. The company generates revenue through its clinical-stage products, particularly its lead investigational product, certepetide, which utilizes a unique technology to enhance the effectiveness of anti-cancer drugs. Strategic partnerships and licensing agreements further support its business model.
What is the highest forecasted price for LSTA Lisata Therapeutics Inc.?
The highest price target for LSTA is $4.00 from at , which represents a 8.1% increase from the current price of $3.70.
What is the lowest forecasted price for LSTA Lisata Therapeutics Inc.?
The lowest price target for LSTA is $4.00 from at , which represents a 8.1% increase from the current price of $3.70.
What is the overall LSTA consensus from analysts for Lisata Therapeutics Inc.?
The overall analyst consensus for LSTA is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are LSTA stock price projections?
Stock price projections, including those for Lisata Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 11:52 AM UTC